Cladribine

Common brands: Mavenclad, Cytarabine, Rituxan, Cyclophosphamide, Frindovyx

Top reporter: Emd Serono, Inc.

Purine Antimetabolite [EPC]Nucleoside Metabolic Inhibitor [EPC]CD20-directed Cytolytic Antibody [EPC]Corticosteroid [EPC]Alkylating Drug [EPC]
9,240
Total Reports
4,883
Serious Reports
698
Death Reports
30
Reported Reactions
Death Report Ratio: High (7.55%)

Patient Demographics

Male
2,586
Female
5,894

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Cladribine.

# Reaction Reports % of Total
1 FATIGUE 789
9.7%
2 HEADACHE 654
8.0%
3 LYMPHOCYTE COUNT DECREASED 471
5.8%
4 MULTIPLE SCLEROSIS RELAPSE 468
5.8%
5 NAUSEA 410
5.0%
6 PNEUMONIA 391
4.8%
7 WHITE BLOOD CELL COUNT DECREASED 348
4.3%
8 OFF LABEL USE 327
4.0%
9 PYREXIA 286
3.5%
10 DRUG INEFFECTIVE 283
3.5%
11 URINARY TRACT INFECTION 271
3.3%
12 MULTIPLE SCLEROSIS 249
3.1%
13 ASTHENIA 234
2.9%
14 LYMPHOPENIA 222
2.7%
15 FEBRILE NEUTROPENIA 209
2.6%
16 COVID-19 197
2.4%
17 DIARRHOEA 193
2.4%
18 PAIN 191
2.3%
19 DIZZINESS 182
2.2%
20 FALL 179
2.2%
21 DEATH 172
2.1%
22 NEUTROPENIA 170
2.1%
23 GAIT DISTURBANCE 169
2.1%
24 SEPSIS 167
2.1%
25 PANCYTOPENIA 163
2.0%
26 VOMITING 158
1.9%
27 LOWER RESPIRATORY TRACT INFECTION 155
1.9%
28 THROMBOCYTOPENIA 149
1.8%
29 INFECTION 144
1.8%
30 WEIGHT DECREASED 135
1.7%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.